NeoTRIPaPDL1 Michelangelo: Neoadjuvant Chemotherapy ± Atezolizumab in Early, High-Risk and Locally Advanced TNBC

December 10-14, 2019; San Antonio, Texas
No significant increase in pCR rate with addition of atezolizumab to carboplatin/nab-paclitaxel in women with early, high-risk and locally advanced TNBC.
Format: Microsoft PowerPoint (.ppt)
File Size: 220 KB
Released: December 19, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

Expert faculty provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Downloadable slides from Dr Denise Yardley on key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Released: September 22, 2022

Downloadable slideset on the role of biomarker testing and practical information on the use of targeted therapies in NSCLC for oncology nurses, from Clinical Care Options (CCO).

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Released: September 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings